ArticlePrecision radiation oncology2025
Efficacy and safety evaluation of radiotherapy approach based on spatially fractionated radiotherapy and stereotactic core ablative radiation therapy technologies for bone metastatic malignant tumors with soft tissue formation: A randomized controlled phase II trial.
Article in Precision radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987370 (A Phase II Randomized Controlled Clinical Study on the Efficacy and Safety Evaluation of Radiotherapy Mode Based on SFRT and SCART Technologies for Bone Metastatic Malignant Tumors With Soft Tissue Formation), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Randomized Controlled Clinical Study on the Efficacy and Safety Evaluation of Radiotherapy Mode Based on SFRT and SCART Technologies for Bone Metastatic Malignant Tumors With Soft Tissue Formation
Who cites it
3 citing papers in PubMed.
- A dosimetric study of photon energy and flattening filter mode combinations in Stereotactic Central Ablative Radiotherapy.Journal of applied clinical medical physics · 2026Article
- Stereotactic centralized ablative radiation therapy: a framework for ultra-heterogeneous radiotherapy of bulky tumors.Frontiers in oncology · 2026Article
- Efficacy and safety evaluation of radiotherapy approach based on spatially fractionated radiotherapy and stereotactic core ablative radiation therapy technologies for bone metastatic malignant tumors with soft tissue formation: A randomized controlled phase II trial.Precision radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Spatially fractionated radiation therapy (SFRT) and stereotactic core ablative radiation therapy (SCART), two novel radiotherapy techniques, have demonstrated distinct advantages in the treatment of large-volume tumors. Both approaches allow precise delivery of high-dose radiation to the tumor core while sparing surrounding organs at risk. The objective of this study is to evaluate the efficacy and safety of these two techniques for the treatment of bone metastases accompanied by soft tissue formation. Method: Patients with bone metastases accompanied by soft tissue formation will be recruited and assigned to the control or experimental groups. The control group will receive conventional radiotherapy (CRT) with 30 Gy delivered in 10 fractions, while the experimental group will undergo tumor core irradiation using SFRT or SCART with a single dose of 8-12 Gy, followed by whole-bone metastatic lesion radiotherapy with 25-40 Gy delivered in 5 fractions. The primary endpoint is the objective response rate, and secondary endpoints include the pain relief, safety, and local control rates. Discussion: This study evaluates the efficacy and tolerability of using SFRT/SCART for treating bone metastases with soft tissue formation, with the expectation of improving local tumor control and reducing treatment-related toxicities. Trial registration: The study was registered at ClinicalTrials.gov with the Identifier: NCT06987370 (Registered May 16, 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.